ReAlta Life Sciences, Inc.: ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023 Annual Meeting
Presenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company's dual action complement inhibitor and innate anti-inflammatory product candidate ReAlta Life Sciences
Source: finanznachrichten.de